Xceleron and JCL Bioassy Offer Combined Solutions for Clinical Investigations

Xceleron, a specialist in the design and use of ultra-sensitive Accelerator Mass Spectrometry (AMS) in novel clinical investigation and JCL Bioassay, a leader in the use of highly sensitive LC-MS/MS and proprietary methodologies, have partnered to offer drug developers across Asia, Europe and North America access to their analytical platforms in early clinical development.

The partnership provides access to clinical design expertise and the most appropriate technologies for investigations. Xceleron and JCL Bioassay have between them developed over 100 analytical methods for Phase 0 and enriched Phase 1 investigations and both companies have recently built, equipped and staffed laboratories specifically for the purpose of ultra-low level analyses under GLP and GCP conditions.

“This partnership emphasises the critical role of contemporary analytical platforms in driving down the cost of drug development. Whether in Phase 0 or enriched Phase I, we can confidently provide critical PK and PD information before Phase II” said Dr Michael Butler, CEO of Xceleron.

“With 27 years’ experience in providing services for bioassay work coupled with-state-of-the-art analytical instruments, our researchers are well positioned to conduct ultrasensitive bioanalyses. This has led to the continuous growth of our company as a leader in the bioanalytical field and enables our customers to make rapid and precise decisions on their drug development programs. The partnership with Xceleron further expands the geographic and technological scope of the services we can provide to our customers and promotes the use of these cutting-edge analytical platforms to detect low level analytes in early drug development” said Jenny Lin, Vice President of Operations and CSO of JCL Bioassay USA, Inc.